Background:

Dronedarone (SR 33589) is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile; it is a multichannel blocker with antiadrenergic properties and has been evaluated in both rate and rhythm control strategies in the management of AF.

参考文献:
[1]. Piccinni C, et al.Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden.Eur J Clin Pharmacol. 2012 Sep 1.
[2]. Benaim G, et al.The emerging role of amiodarone and dronedarone in Chagas disease.Nat Rev Cardiol. 2012 Aug 7.
[3]. Rosman J, et al. Possible Proarrhythmia with Dronedarone.J Cardiovasc Electrophysiol. 2012 Jul 19.
[4]. Kao DP, et al. Proarrhythmic Potential of Dronedarone: Emerging Evidence from Spontaneous Adverse Event Reporting.Pharmacotherapy. 2012 Jun 28.
[5]. Manakshe G, Rao BH.Dronedarone-current status in management of atrial fibrillation.Indian Heart J. 2012 Mar-Apr;64(2):182-6. Epub 2012 Apr 28.